Neuroceuticals: The New Face of Medical Device Engineering
Follow Neuroceuticals on :
Shinya Miike, President and CEO
Endoscopic treatment or medical techniques are the future of healthcare, with the call for less invasive procedures continuing to rise amongst patients, especially aged individuals. As physicians rally behind the same idea, these procedures are set to become the norm across medical facilities and institutions. While endoscopy has been in the healthcare operational forte for decades, modern technology advancements allow the devices to be further brought down in size and for hospitals to use them across newer treatment sectors. A pioneer of the space, Shinya Miike, CEO and President at Neuroceuticals, has an outstanding track record for designing and developing such medical equipment and is credited with building one of the world’s most ultrathin endoscopes to date. With a career that started in 1998, Miike has worked with many large healthcare technology/ medical device companies across the globe
“Working in the medical device space, I have met a brilliant team of physicians from the Kyushu area, and along with them established Neuroceuticals to develop unique medical devices by combining our experience and expertise,” says Miike. The focus at Neuroceuticals is on the development of an intravenous vagal nerve stimulation catheter, and the project that is funded by the Japanese Government is expected to go to clinical trials in the first half of 2022. As no similar device exists for this type of medical procedure, Neuroceuticals will be the first to develop the system that will allow for cardioplegia by vagal nerve stimulation.
The additional value of Neuroceuticals’ inbuilt proprietary technology algorithm will also help physicians ensure that the appropriate and accurate stimulation is performed efficiently.
In addition to designing and developing exquisite intravenous and endoscopic medical devices, Neuroceuticals also has an up to date understanding of the Japanese regional regulations, and all equipment is being prepared to comply with the laws. This facet allows Neuroceuticals to offer services to other nonJapanese companies looking to enter the Japanese market. Based on the experience of its leader, Neuroceuticals has built many relationships with medical-device experts as well as venture capital firms where new ideas are pondered, and funding secured at the end of a successful pitch. “We help develop new advanced medical technology devices that are beneficial for both the physician and patient,” elucidates Miike.
With a wide variety of projects in the pipeline, Neuroceuticals conducts extensive research in delivering the best end product to the medical market for intravenous treatment of patients. As the devices are reduced in size, the raw material used is lesser as compared to its predecessors and increases the time and cost savings for a hospital or other medical institutions. Garnering a unique skill set to develop and deliver such products, Neuroceuticals will offer an extensive range of solutions that could address concerns pertaining to a larger part of the medical society, such as ophthalmology, brain, vascular, and lung specialists, while also reducing the burden for patients and their caretakers.
In the road ahead, with an aspiration to improve the quality of life for patients as a medical device idea generator and developer, Neuroceuticals concentrates not only on the product build but also the digital application and other core components that can create value for all medical stakeholders. From a diagnosis and treatment perspective, the company works very closely with research institutes and clinical sites to better read the requirements and create devices that physicians require to treat patients with less invasion and little pain.
Description A medical device developer and idea generator that works both on in-house projects as well as collaborations with other similar healthcare technology providers.The focus at Neuroceuticals is on the development of an intravenous vagal nerve stimulation catheter, and the project that is funded by the Japanese Government is expected to go to clinical trials in the first half of 2022.In addition to designing and developing exquisite intravenous and endoscopic medical devices, Neuroceuticals also has an up to date understanding of the Japanese regional regulations, and all equipment is being prepared to comply with the laws. This facet allows Neuroceuticals to offer services to other non-Japanese companies looking to enter the Japanese market.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: